BioSpring has nearly three decades of expertise in manufacturing a wide range of nucleic acid modalities, making us a trusted partner across pharma, biotech, and academia. From preclinical development to commercial production, we ensure the highest quality across all manufacturing grades and scales. With unmatched precision and reliability, we help you accelerate your therapeutic nucleic acid programs from bench to bedside.
Broadest expertise in the industry, including:
Most approved nucleic acid therapeutics today rely on a range of chemical modifications to enhance their stability, efficacy, and safety. At BioSpring, we have extensive experience with conjugation chemistries, including conjugating oligonucleotides to sugars (e.g., GalNAc), lipids, and peptides. We also offer the capability to manufacture oligonucleotides with a variety of linkers that enable antibody conjugation. Whether your program requires straightforward molecules or more complex modifications, we enable the development of next-generation nucleic acid therapeutics that are more effective and durable.
Our modification capabilities for oligonucleotides:
